Consultant Physician and Honorary Professor, Sherwood Forest hospitals NHS Trust, University of Nottingham, UK.
Parkinsonism Relat Disord. 2010 Sep;16(8):490-7. doi: 10.1016/j.parkreldis.2010.06.003. Epub 2010 Jul 3.
Currently there is no classification of risk factors applicable to an individual patient with Parkinson's disease for the development of dyskinesia.
We conducted literature search to identify and classifying risk factors into groups - (a) intrinsic vs extrinsic and (b) modifiable vs non-modifiable.
Younger age, young age of onset and severity of PD are major intrinsic non-modifiable risk factors for dyskinesia, female gender is another factor but not independent of other factors. Genetic expression and plasticity may determine pre-disposition to age of onset of PD and dyskinesia, these are currently non-modifiable factors arising due to an interaction of intrinsic and extrinsic factors. Lower initial body weight and weight loss during the course of the disease increase the risk of dyskinesia. Levodopa dose per kilogram body weight is a more significant risk factor than absolute levodopa dose. Early use of longer acting non-levodopa (i.e. dopamine agonists) medications delays the onset of dyskinesia. Interaction between body weight, levodopa dose and mode and duration of drug delivery is a significant modifiable factor.
Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia.
目前尚无适用于个体帕金森病患者发生运动障碍的风险因素分类。
我们进行了文献检索,将风险因素分为两组 - (a) 内在与外在,(b) 可改变与不可改变。
年龄较小、发病年龄较小和帕金森病的严重程度是运动障碍的主要内在不可改变的风险因素,女性是另一个因素,但不是独立于其他因素。遗传表达和可塑性可能决定帕金森病和运动障碍的发病年龄,这些目前是由于内在和外在因素相互作用而产生的不可改变的因素。初始体重较低和疾病过程中的体重减轻会增加运动障碍的风险。每公斤体重的左旋多巴剂量比绝对左旋多巴剂量更重要的风险因素。早期使用长效非左旋多巴(即多巴胺激动剂)药物可延迟运动障碍的发生。体重、左旋多巴剂量以及药物输送的方式和持续时间之间的相互作用是一个重要的可改变因素。
帕金森病中的运动障碍是内在与外在以及可改变与不可改变因素相互作用的结果。确定个体患者的可改变因素并加以处理可能会降低运动障碍的风险和负担。根据疾病过程中的体重调整左旋多巴剂量似乎是运动障碍的一个重要可改变风险因素。